News
AI dominates China’s elite doctors in cancer diagnosis competition
A custom-built AI designed to diagnose brain tumors and predict hematoma expansion dominated some of China’s best doctors in a competition last Saturday in Beijing. The AI, dubbed BioMind, ultimately scored 2:0 against its human competitors, comprised of 15 senior doctors from China’s premier hospitals.
BioMind was developed by a collaboration between a team from the Artificial Intelligence Research Center for Neurological Disorders at the Beijing Tiantan Hospital and researchers from the Capital Medical University. BioMind’s developers opted to feed the AI with data sets featuring tens of thousands of images depicting nervous-system-related diseases, which were retrieved from Tiantan Hospital’s archives stretching over the past decade.
Wang Yongjun, executive vice-president of Tiantan Hospital, stated that this training ultimately enabled the AI to become proficient in diagnosing neurological diseases such as meningioma and glioma with an accuracy rate of over 90%. According to Wang, such rates are comparable to the accuracy of a senior doctor, according to a report from state-owned Xinhua News.
During its the competition on Saturday, BioMind was able to correctly diagnose brain tumors with an accuracy rate of 87% out of a total of 225 cases. The AI was also able to complete its task in 15 minutes. In comparison, the team of 15 elite doctors was able to achieve an accuracy rate of 66% when diagnosing brain tumors, finishing the task in 30 minutes. Apart from this, BioMind was able to make correct predictions in 83% of brain hematoma expansion cases, while its human competition displayed a more conservative 63% accuracy.
Despite the AI’s strong performance against China’s elite doctors on Saturday, however, Cheng Jingliang, a professor of radiology at the First Affiliated Hospital of Zhengzhou University, stated that artificial intelligence systems for the medical field are still well into their infancy. According to Cheng, AI is already being used in hospitals to help doctors read images such as lung scans, but when it comes to giving full diagnoses to patients, artificial intelligence still lags far behind that of senior medical professionals.
In a statement to China Daily, Paul Parizel from the Antwerp University Hospital in Belgium, who served as a member of the jury during last Saturday’s AI vs. human doctors competition, believes that systems such as BioMind would prove to be incredibly valuable when integrated to existing medical practices.
“It will be like a GPS guiding a car. It will make proposals to a doctor and help the doctor diagnose. But it will be the doctor who ultimately decides, as there are a number of factors that a machine cannot take into consideration, such as a patient’s state of health and family situation,” he said.
The United States initially led the artificial intelligence race, but over the years, China has steadily gained ground in the AI industry. Thanks to a population that is compliant to the application of new technologies, as well as a government that actively pushes AI researchers to push further, China is on track to overtake the United States in the near future. Last January alone, the Chinese government announced plans to build a $2.1 billion technopark in Beijing that is expected to house companies actively involved in AI research and development. The United States does not have a comparable initiative to date. This was confirmed by Jack Clark of Elon Musk-backed OpenAI, who previously stated that the country lacks a central national strategy on artificial intelligence.
“It is confusing that we have this technology of such obvious power and merit and we are not hearing full-throated support, including financial support,” Clark said.
Elon Musk
SpaceX issues statement on Starship V3 Booster 18 anomaly
The incident unfolded during gas-system pressure testing at the company’s Massey facility in Starbase, Texas.
SpaceX has issued an initial statement about Starship Booster 18’s anomaly early Friday. The incident unfolded during gas-system pressure testing at the company’s Massey facility in Starbase, Texas.
SpaceX’s initial comment
As per SpaceX in a post on its official account on social media platform X, Booster 18 was undergoing gas system pressure tests when the anomaly happened. Despite the nature of the incident, the company emphasized that no propellant was loaded, no engines were installed, and personnel were kept at a safe distance from the booster, resulting in zero injuries.
“Booster 18 suffered an anomaly during gas system pressure testing that we were conducting in advance of structural proof testing. No propellant was on the vehicle, and engines were not yet installed. The teams need time to investigate before we are confident of the cause. No one was injured as we maintain a safe distance for personnel during this type of testing. The site remains clear and we are working plans to safely reenter the site,” SpaceX wrote in its post on X.
Incident and aftermath
Livestream footage from LabPadre showed Booster 18’s lower half crumpling around the liquid oxygen tank area at approximately 4:04 a.m. CT. Subsequent images posted by on-site observers revealed extensive deformation across the booster’s lower structure. Needless to say, spaceflight observers have noted that Booster 18 would likely be a complete loss due to its anomaly.
Booster 18 had rolled out only a day earlier and was one of the first vehicles in the Starship V3 program. The V3 series incorporates structural reinforcements and reliability upgrades intended to prepare Starship for rapid-reuse testing and eventual tower-catch operations. Elon Musk has been optimistic about Starship V3, previously noting on X that the spacecraft might be able to complete initial missions to Mars.
Investor's Corner
Tesla analyst maintains $500 PT, says FSD drives better than humans now
The team also met with Tesla leaders for more than an hour to discuss autonomy, chip development, and upcoming deployment plans.
Tesla (NASDAQ:TSLA) received fresh support from Piper Sandler this week after analysts toured the Fremont Factory and tested the company’s latest Full Self-Driving software. The firm reaffirmed its $500 price target, stating that FSD V14 delivered a notably smooth robotaxi demonstration and may already perform at levels comparable to, if not better than, average human drivers.
The team also met with Tesla leaders for more than an hour to discuss autonomy, chip development, and upcoming deployment plans.
Analysts highlight autonomy progress
During more than 75 minutes of focused discussions, analysts reportedly focused on FSD v14’s updates. Piper Sandler’s team pointed to meaningful strides in perception, object handling, and overall ride smoothness during the robotaxi demo.
The visit also included discussions on updates to Tesla’s in-house chip initiatives, its Optimus program, and the growth of the company’s battery storage business. Analysts noted that Tesla continues refining cost structures and capital expenditure expectations, which are key elements in future margin recovery, as noted in a Yahoo Finance report.
Analyst Alexander Potter noted that “we think FSD is a truly impressive product that is (probably) already better at driving than the average American.” This conclusion was strengthened by what he described as a “flawless robotaxi ride to the hotel.”
Street targets diverge on TSLA
While Piper Sandler stands by its $500 target, it is not the highest estimate on the Street. Wedbush, for one, has a $600 per share price target for TSLA stock.
Other institutions have also weighed in on TSLA stock as of late. HSBC reiterated a Reduce rating with a $131 target, citing a gap between earnings fundamentals and the company’s market value. By contrast, TD Cowen maintained a Buy rating and a $509 target, pointing to strong autonomous driving demonstrations in Austin and the pace of software-driven improvements.
Stifel analysts also lifted their price target for Tesla to $508 per share over the company’s ongoing robotaxi and FSD programs.
Elon Musk
SpaceX Starship Version 3 booster crumples in early testing
Photos of the incident’s aftermath suggest that Booster 18 will likely be retired.
SpaceX’s new Starship first-stage booster, Booster 18, suffered major damage early Friday during its first round of testing in Starbase, Texas, just one day after rolling out of the factory.
Based on videos of the incident, the lower section of the rocket booster appeared to crumple during a pressurization test. Photos of the incident’s aftermath suggest that Booster 18 will likely be retired.
Booster test failure
SpaceX began structural and propellant-system verification tests on Booster 18 Thursday night at the Massey’s Test Site, only a few miles from Starbase’s production facilities, as noted in an Ars Technica report. At 4:04 a.m. CT on Friday, a livestream from LabPadre Space captured the booster’s lower half experiencing a sudden destructive event around its liquid oxygen tank section. Post-incident images, shared on X by @StarshipGazer, showed notable deformation in the booster’s lower structure.
Neither SpaceX nor Elon Musk had commented as of Friday morning, but the vehicle’s condition suggests it is likely a complete loss. This is quite unfortunate, as Booster 18 is already part of the Starship V3 program, which includes design fixes and upgrades intended to improve reliability. While SpaceX maintains a rather rapid Starship production line in Starbase, Booster 18 was generally expected to validate the improvements implemented in the V3 program.
Tight deadlines
SpaceX needs Starship boosters and upper stages to begin demonstrating rapid reuse, tower catches, and early operational Starlink missions over the next two years. More critically, NASA’s Artemis program depends on an on-orbit refueling test in the second half of 2026, a requirement for the vehicle’s expected crewed lunar landing around 2028.
While SpaceX is known for diagnosing failures quickly and returning to testing at unmatched speed, losing the newest-generation booster at the very start of its campaign highlights the immense challenge involved in scaling Starship into a reliable, high-cadence launch system. SpaceX, however, is known for getting things done quickly, so it would not be a surprise if the company manages to figure out what happened to Booster 18 in the near future.
SpaceX issues statement on Starship V3 Booster 18 anomaly
Tesla analyst maintains $500 PT, says FSD drives better than humans now
